CA2606624C - Methodes et compositions pour le traitement et la prevention de la malaria (2) - Google Patents

Methodes et compositions pour le traitement et la prevention de la malaria (2) Download PDF

Info

Publication number
CA2606624C
CA2606624C CA2606624A CA2606624A CA2606624C CA 2606624 C CA2606624 C CA 2606624C CA 2606624 A CA2606624 A CA 2606624A CA 2606624 A CA2606624 A CA 2606624A CA 2606624 C CA2606624 C CA 2606624C
Authority
CA
Canada
Prior art keywords
residue
invasion
amino acid
seq
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2606624A
Other languages
English (en)
Other versions
CA2606624A1 (fr
Inventor
Alan Cowman
James Beeson
Alexander Gerd Maier
Kristina E.M. Persson
Jonathan S. Richards
Sash Lopaticki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Original Assignee
Walter and Eliza Hall Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter and Eliza Hall Institute of Medical Research filed Critical Walter and Eliza Hall Institute of Medical Research
Priority to CA2606624A priority Critical patent/CA2606624C/fr
Publication of CA2606624A1 publication Critical patent/CA2606624A1/fr
Application granted granted Critical
Publication of CA2606624C publication Critical patent/CA2606624C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
    • G01N2333/445—Plasmodium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Des vaccins, notamment des antigènes pouvant stimuler des anticorps permettant dempêcher une invasion du parasite plasmodium dans des érythrocytes et utilisation desdits vaccins pour le traitement et/ou la prévention de la malaria. Dans un mode de réalisation, lantigène est une molécule immunogène comprenant une séquence aminoacide contiguë dune protéine antigène se liant aux érythrocytes dune souche de Plasmodium falciparum. Lorsquelle est administrée à un sujet, la molécule est capable dinduire une réponse immunitaire inhibitrice dinvasion à la source. Un procédé pour dépister la présence dun anticorps inhibiteur dinvasion Plasmodium falciparum dirigé contre un antigène se liant aux érythrocytes dune souche de Plasmodium falciparum chez un sujet est également décrit.
CA2606624A 2007-11-05 2007-11-05 Methodes et compositions pour le traitement et la prevention de la malaria (2) Expired - Fee Related CA2606624C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2606624A CA2606624C (fr) 2007-11-05 2007-11-05 Methodes et compositions pour le traitement et la prevention de la malaria (2)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2606624A CA2606624C (fr) 2007-11-05 2007-11-05 Methodes et compositions pour le traitement et la prevention de la malaria (2)

Publications (2)

Publication Number Publication Date
CA2606624A1 CA2606624A1 (fr) 2009-05-05
CA2606624C true CA2606624C (fr) 2017-06-20

Family

ID=40620852

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2606624A Expired - Fee Related CA2606624C (fr) 2007-11-05 2007-11-05 Methodes et compositions pour le traitement et la prevention de la malaria (2)

Country Status (1)

Country Link
CA (1) CA2606624C (fr)

Also Published As

Publication number Publication date
CA2606624A1 (fr) 2009-05-05

Similar Documents

Publication Publication Date Title
US9134311B2 (en) Methods and compositions for treating and preventing malaria using an invasion ligand directed to a protease-resistant receptor
López et al. What is known about the immune response induced by Plasmodium vivax malaria vaccine candidates?
Nikolaeva et al. Toward the development of effective transmission-blocking vaccines for malaria
US9109040B2 (en) Treatment and prevention of malaria
US8703147B2 (en) Methods and compositions for treating and preventing malaria (2)
JP6461100B2 (ja) アピコンプレクサ病原体に対する新規ワクチン
US9884101B2 (en) Treatment and prevention of malaria
US20090175895A1 (en) Methods and compositions for treating and preventing malaria
Mazumdar et al. Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response
Anders et al. Antigenic repeat structures in proteins of Plasmodium falciparum
Patarroyo et al. Functionally relevant proteins in Plasmodium falciparum host cell invasion
US20070098738A1 (en) MSP-3-like family of genes
AU2007231854B2 (en) Methods and compositions for treating and preventing malaria (2)
CA2606624C (fr) Methodes et compositions pour le traitement et la prevention de la malaria (2)
CA2610100A1 (fr) Methodes et compositions pour le traitement et la prevention de la malaria
WO2009094726A1 (fr) Polynucléotides plasmodiaux, protéines plasmodiales et leurs utilisations
AU2007231853A1 (en) Methods and compositions for treating and preventing malaria
Good et al. T-cell antigens and epitopes in malaria vaccine design
Pluschke et al. Development of a virosomal malaria vaccine candidate: from synthetic peptide design to clinical concept validation
Ramasamy Protective antigens, immune mechanisms and synthetic vaccines in malaria-1994
Ramasamy et al. Progress towards a molecular vaccine against malaria
Alaro Development of a novel chimeric blood-stage malaria vaccine
Redmond et al. The Australasian contribution to malaria vaccine development
Semenya Merozoite invasion of erythrocytes: Revealing functional characteristics of the Plasmodium knowlesi Normocyte Binding Proteins
RAMASAMY J. Natn. Sci. Coun. Sri Lanka 1994 22 (2): 93-114 REVIEW PROTECTIVE ANTIGENS, IMMUNE MECHANISMS AND SYNTHETIC VACCINES IN MALAR, IA-1994

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20191105